Key result
Preemptive treatment with ganciclovir directed by high levels of CMV antigenemia significantly reduced the incidence of CMV disease compared to historical controls (0% vs 27.8%; P=0.019).
Why the study?
Does preemptive treatment with ganciclovir directed by CMV antigenemia reduce the incidence of CMV disease in at-risk patients?
Population
37 patients at risk of cytomegalovirus pneumonitis
Comparison
Preemptive treatment with ganciclovir, 10… vs Historical controls treated with ganciclovir…
Design
Cohort
Authors
Loading...
May support preemptive ganciclovir for CMV antigenemia in transplant recipients; hypothesis-generating and requires randomized confirmation.
Cohort (n=37)
Does preemptive treatment with ganciclovir directed by CMV antigenemia reduce the incidence of CMV disease in at-risk patients?
Absolute Event Rate: 0% vs 27.8%
p-value: p=0.019
Preemptive treatment with ganciclovir guided by CMV antigenemia surveillance significantly reduces the incidence of CMV disease compared to treating only when illness occurs.
Egan et al. (1998) conducted a cohort in Cytomegalovirus (CMV) infection (n=37). Preemptive treatment with ganciclovir directed by high levels of CMV antigenemia vs. Historical controls treated with ganciclovir when CMV illness occurred was evaluated on Incidence of CMV disease (p=0.019). Preemptive treatment with ganciclovir directed by high levels of CMV antigenemia significantly reduced the incidence of CMV disease compared to historical controls (0% vs 27.8%; P=0.019).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: